U.S. Biotech Stock News

Enphase Energy has already begun U.S. production shipments of its IQ9N-3P Commercial Microinverter, a gallium nitride–based, three-phase 480Y/277 V device built domestically to meet content and FEOC compliance requirements for commercial solar projects. The launch extends Enphase’s panel-level microinverter architecture into the 480 V commercial market, aiming to simplify system design, trim installation costs, and enhance per-panel monitoring and safety for complex rooftop...

Bloom Energy (BE) is back in the spotlight after a fresh $2.65b expansion of its American Electric Power partnership for solid oxide fuel cells tied to AI hungry data centers. See our latest analysis for Bloom Energy. The latest American Electric Power deal comes after several AI focused data center wins, a multi billion dollar arrangement with Brookfield Asset Management, and a new US$600m credit facility that increased Bloom Energy’s financial flexibility. Against that backdrop, the share...

Edgewise Therapeutics (EWTX) shares were in focus after the company outlined a packed 2026 clinical calendar, detailing timelines for pivotal trials, planned regulatory filings, and key readouts across its muscle and cardiovascular programs. See our latest analysis for Edgewise Therapeutics. The recent clinical roadmap has coincided with strong momentum in the share price, with a 59.73% 90 day share price return but a 9.34% decline in 1 year total shareholder return. The 3 year total...

American Airlines recently partnered with award-winning Pecan Lodge to offer Texas-style barbecue on select Dallas–Fort Worth to New York routes and received multiple analyst upgrades citing fleet renewal and premium product focus. Together, these moves highlight how American is leaning on differentiated customer experience and analysts’ improving views of its business direction to influence investor sentiment. We'll now explore how American’s premium-focused initiatives, such as the Pecan...

If you are wondering whether CareDx at around US$20.19 is starting to look interesting again, you are not alone. This article is here to help you think through the value question. The share price has seen a 7.3% gain over the last week, while the 30 day return sits at a 1.8% decline and the 1 year return is a 8.4% decline. This is against a 42.3% gain over 3 years and a 78.4% decline over 5 years. Recent news coverage of CareDx has focused on how investors are reassessing the company in...

Tradeweb Markets Inc. reported past record total trading volume of $63.0 trillion for December 2025 and $185.3 trillion for the fourth quarter, with average daily volume for both periods rising very large year over year and preliminary fee metrics highlighting the scale of its electronic trading activity. The combination of surging volumes and disclosed preliminary variable and fixed fees offers a clearer view of how Tradeweb is converting higher activity into revenue. Next, we will examine...

Biogen recently received European Commission marketing authorization for a high-dose SPINRAZA regimen to treat 5q spinal muscular atrophy, covering rapid-loading 50 mg doses followed by 28 mg maintenance injections every four months. This decision, grounded in the DEVOTE Phase 2/3 trial showing statistically significant motor function gains with a safety profile consistent with nusinersen, meaningfully broadens treatment options for the vast majority of SMA patients in Europe. We’ll now...

Alumis (ALMS) is back in focus after reporting positive Phase 3 ONWARD1 and ONWARD2 results for its TYK2 inhibitor envudeucitinib in plaque psoriasis, followed by a completed US$300.05 million follow-on equity offering. See our latest analysis for Alumis. The upbeat Phase 3 data and follow on equity offering have coincided with strong near term momentum, with a 30 day share price return of 92.43% and a year to date share price return of 146.90%, while the 1 year total shareholder return of...

If you are wondering whether Coeur Mining's recent share price puts it at an attractive entry point, the next sections will walk through what the current valuation might be telling you. The stock last closed at US$20.96, with reported returns of 6.8% over 7 days, 21.5% over 30 days, 19.4% year to date and 230.1% over the past year. This naturally raises questions about both opportunity and risk at today’s price. Investors have been reacting to company specific developments and broader moves...

UBS’ decision to downgrade Perimeter Solutions (PRM) from Buy to Neutral, while the company funds its Medical Manufacturing Technologies acquisition through a $550 million note offering, has put the stock’s risk and return trade off in sharper focus. See our latest analysis for Perimeter Solutions. At a share price of $28.08, Perimeter Solutions has seen a 24.58% 3 month share price return and a 116.33% 1 year total shareholder return. This suggests recent momentum remains positive even as...

Western Digital’s recent spin-off of its flash business and sharpened focus on hard disk drives for data centers have intersected with bullish trading signals, including repeated tests of a key technical resistance level and strong order-flow “Power Inflow” alerts earlier this month. This combination of a more specialized business model and concentrated buying activity highlights how AI-driven data center demand and hyperscaler spending are increasingly central to Western Digital’s current...

If you are wondering whether Zai Lab's current share price lines up with its underlying worth, this article walks through the numbers so you can form your own view. Zai Lab's stock closed at US$18.72, with returns of 2.9% over the last 7 days, 5.3% over the last 30 days and 8.0% year to date, while the 1 year, 3 year and 5 year returns stand at a 22.9% decline, 58.5% decline and 89.9% decline respectively. Recent share price moves sit against an ongoing flow of company updates and sector...

Wealthfront (WLTH) just posted its Q3 2026 numbers, with revenue of US$93.2 million, basic EPS of US$0.72 and trailing twelve month EPS of US$3.04 setting the backdrop for the quarter. The company has seen revenue move from US$80.3 million in Q3 2025 to US$93.2 million in Q3 2026, while quarterly EPS has shifted from US$0.77 to US$0.72 over the same period, against trailing twelve month revenue of US$351.5 million. With a current net profit margin of 35.2% versus 57.7% a year ago, this update...

Morgan Stanley recently initiated coverage on GRAIL (GRAL.US) with a hold rating, as analyst Kallum Titchmarsh issued his first formal view on the company. This new coverage introduces an additional institutional lens on GRAIL’s multi-cancer early detection business, potentially shaping how investors interpret its risk‑reward profile. We'll now examine how Morgan Stanley's new hold rating interacts with expectations for Galleri adoption, profitability paths, and long-term earnings...

If you are wondering whether Intercontinental Exchange at around US$166 per share offers reasonable value today, the key is understanding how its current price lines up with different valuation yardsticks. The stock has recently posted returns of 0.4% over 7 days, 2.1% over 30 days, 4.2% year to date, 16.1% over 1 year, 61.3% over 3 years, and 54.7% over 5 years, which gives useful context for how the market has been pricing its prospects and risks. Recent coverage around Intercontinental...

Wondering if Celsius Holdings is still reasonably priced after its strong run, or if the value case is already played out? This article is built to help you size that up with clear valuation checks. The stock last closed at US$52.61, with returns of 8.1% over 7 days, 20.0% over 30 days, 10.2% year to date and 95.8% over 1 year, which naturally raises questions about how much future upside or risk is already reflected in the price. Recent attention on Celsius has centered on its position in...

Eos Energy Enterprises recently hosted its “Eos in Focus” event on January 14, where management reviewed full-year 2025 financial and operating results and outlined its business outlook for 2026. This update is important because it gives investors fresh detail on how Eos’s scale-up and technology roadmap are progressing against its long-term plans. We’ll now examine how the fresh operational and 2026 outlook detail from “Eos in Focus” could influence Eos’s investment narrative. The latest...

Conference spotlight and product news put Elanco in focus Elanco Animal Health (ELAN) is drawing fresh attention after securing U.S. Department of Agriculture approval for its new canine dermatitis treatment, Befrena, and outlining its plans ahead of its J.P. Morgan Healthcare Conference appearance. See our latest analysis for Elanco Animal Health. Those product updates and the J.P. Morgan appearance come as Elanco’s share price sits at $24.45, with a 30 day share price return of 14.84% and a...

TransMedics Group (TMDX) has committed to a long-term lease for a new global headquarters at Assembly Innovation Park in Somerville, and it has acquired adjacent land to build an integrated campus and expand its transplant therapy operations. See our latest analysis for TransMedics Group. The headquarters announcement follows a period of strong recent momentum, with a 1-day share price return of 5.98% lifting TransMedics Group to US$142.71 and contributing to a 30-day share price return of...

Ciena recently delivered fiscal fourth-quarter results that surpassed analyst expectations and issued optimistic fiscal 2026 guidance, highlighting anticipated revenue growth and stronger operating margins. The CEO also emphasized Ciena’s reinforced position in high-speed connectivity and its growing role in AI-related network infrastructure, underscoring the company’s importance in supporting data-intensive workloads. We’ll now examine how Ciena’s stronger-than-expected quarter and upbeat...

In early January 2026, Nuvation Bio Inc. and Eisai Co. Ltd. announced an exclusive license and collaboration agreement granting Eisai rights to develop, register and commercialize taletrectinib (IBTROZI) for ROS1-positive non-small cell lung cancer across Europe, large parts of Asia-Pacific, the Middle East, North Africa, Russia, Turkey, Canada, Australia, New Zealand and India, in return for an upfront payment of €50 million (about US$60 million), up to €145 million (about US$170 million)...

If you are wondering whether Marriott International's share price still reflects fair value after a strong run, you are not alone. The stock last closed at US$322.96, with returns of 0.3% over 7 days, 8.1% over 30 days, 3.0% year to date, 18.0% over 1 year and 106.7% over 3 years, while the 5 year return stands at 164.0%. Recent coverage of Marriott has focused on its position as a major global hotel operator and how investors are thinking about long term travel demand and corporate travel...

Apellis Pharmaceuticals (APLS) has drawn fresh attention after reporting preliminary 2025 U.S. net product revenue of about US$689 million, led by demand for SYFOVRE, along with early EMPAVELI uptake and new pipeline updates. See our latest analysis for Apellis Pharmaceuticals. Despite the revenue update and ongoing work on SYFOVRE and EMPAVELI, Apellis’ share price has come under pressure, with a 30 day share price return of a 15.46% decline and a 1 year total shareholder return of a 22.97%...

Recent analyst upgrades on Sea (SE) have put fresh attention on the stock after a pullback from its 2025 high, highlighting how Shopee’s VIP program and fulfillment investments might reshape the risk reward profile for investors. See our latest analysis for Sea. Sea’s shares have been under pressure recently, with a 7 day share price return of 9.12% and a 90 day share price return of 20.54%. This is occurring even though the 1 year total shareholder return is 17.58% and the 3 year total...